Apollo Hospitals Enterprise Limited AI Stock Analysis
Want to see IN:APOLLOHOSP full AI Analyst Report?
Apollo Hospitals Enterprise Limited (APOLLOHOSP) AI Stock Analysis
Apollo Hospitals Enterprise Limited
(NSE:APOLLOHOSP)
The score is supported primarily by improving fundamentals (faster revenue growth, expanding margins, and strong ROE), but is held back by premium valuation (high P/E and low yield) and weaker near-term technicals (negative MACD and price below short-term moving averages).
Apollo Hospitals Enterprise Limited (APOLLOHOSP) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 1.23T
- Dividend Yield
- 0.23%
- Average Volume (3M)
- 37.54K
- Price to Earnings (P/E)
- 54.7
- Beta (1Y)
- 0.72
- Revenue Growth
- 19.24%
- EPS Growth
- 34.11%
- Country
- India
- Employees
- 44,008
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Care Facilities
Apollo Hospitals Enterprise Limited Business Overview & Revenue Model
Company Description
Apollo Hospitals Enterprise Limited, through its group entities, delivers a comprehensive range of medical services both within India and across international borders. Its medical infrastructure spans primary, secondary, and tertiary levels of care....
How the Company Makes Money
Apollo Hospitals Enterprise Limited primarily generates revenue by delivering healthcare services across its hospital network and related healthcare businesses. Key revenue streams include: (1) Hospital services: Income from inpatient and outpatient...
Apollo Hospitals Enterprise Limited Financial Statement Overview
Summary
Strong 2026 acceleration in revenue growth (+8.4%) with improving profitability (net margin ~7.7%, operating margin ~11.5%) and higher ROE (~20.5%). Offsets are moderately high and rising leverage (debt-to-equity ~0.90) plus weaker and choppier cash conversion (FCF ~27% of net income and volatility in recent years).
Income Statement
76PositiveBalance Sheet
70PositiveCash Flow
62Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 277.41B | 252.28B | 217.94B | 190.59B | 166.13B | 146.63B |
| Gross Profit | 105.13B | 82.77B | 73.50B | 63.98B | 56.68B | 51.31B |
| EBITDA | 41.31B | 39.87B | 30.33B | 23.94B | 20.65B | 21.89B |
| Net Income | 22.42B | 19.42B | 14.46B | 8.99B | 8.19B | 10.56B |
Balance Sheet | ||||||
| Total Assets | 242.22B | 221.97B | 206.57B | 167.53B | 144.28B | 131.92B |
| Cash, Cash Equivalents and Short-Term Investments | 23.81B | 21.33B | 27.93B | 11.89B | 7.26B | 10.48B |
| Total Debt | 81.49B | 84.93B | 78.64B | 53.33B | 43.32B | 40.68B |
| Total Liabilities | 130.65B | 122.22B | 120.05B | 94.33B | 78.96B | 73.15B |
| Stockholders Equity | 106.04B | 94.80B | 82.12B | 69.35B | 61.97B | 56.23B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 7.12B | 2.16B | 7.83B | 2.49B | 9.71B |
| Operating Cash Flow | 0 | 26.74B | 19.29B | 19.20B | 13.77B | 16.28B |
| Investing Cash Flow | 0 | -22.44B | -34.77B | -15.37B | -8.71B | -8.47B |
| Financing Cash Flow | 0 | -2.00B | 16.21B | -3.11B | -6.33B | -7.93B |
Apollo Hospitals Enterprise Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APOLLOHOSP, the sentiment is Positive. The current price of 8515.50 is above the 20-day moving average (MA) of 8160.78, above the 50-day MA of 8376.32, and above the 200-day MA of 8144.13, indicating a bullish trend. The MACD of 91.46 indicates Negative momentum. The RSI at 58.16 is Neutral, neither overbought nor oversold. The STOCH value of 66.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:APOLLOHOSP.
Apollo Hospitals Enterprise Limited Peers Comparison
Overall Rating
IN:MEDANTA79Outperform
IN:NH67Neutral
IN:MAXHEALTH63Neutral
IN:APOLLOHOSP59Neutral
IN:FORTIS59Neutral
IN:ASTERDM55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | INR 390.83B | 63.16 | ― | 0.07% | 26.18% | 10.09% | |
| 67Neutral | INR 380.62B | 44.06 | ― | 0.24% | 71.40% | 1.76% | |
| 63Neutral | INR 919.79B | 66.79 | ― | 0.21% | 15.17% | 1.63% | |
| 59Neutral | INR 1.22T | 54.67 | ― | 0.23% | 19.24% | 34.11% | |
| 59Neutral | INR 577.54B | 55.52 | ― | 0.13% | 17.50% | 2.40% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | INR 629.52B | 99.93 | ― | 0.55% | 50.47% | 10.73% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:APOLLOHOSP | Apollo Hospitals Enterprise Limited | 8515.50 | 1045.73 | 14.00% | |
| IN:ASTERDM | Aster DM Healthcare Ltd. | 722.20 | 43.85 | 6.46% | |
| IN:FORTIS | Fortis Healthcare Ltd. | 765.00 | -178.15 | -18.89% | |
| IN:MAXHEALTH | Max Healthcare Institute Ltd | 945.00 | -174.91 | -15.62% | |
| IN:MEDANTA | Global Health Limited | 1453.55 | 249.78 | 20.75% | |
| IN:NH | Narayana Hrudayalaya Ltd. | 1862.50 | -160.90 | -7.95% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 24, 2026
